Aptinyx (APTX) Plans Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall St futures climb ahead of this week's megacap earnings
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threatÂ
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- Wall St futures climb ahead of this week's megacap earnings
- IREN raises 2026 revenue target to $4bn after $2.8bn in contracts
- AMC Entertainment posts record quarterly revenue and EBITDA in Q2 2026
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight
- AMC Entertainment (AMC) Tops Q2 EPS by 16c
Aptinyx (APTX) Prices 10.17M Share Common Stock Offering at $3/shh
January 10, 2020 9:01 AM ESTAptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its public offering of 10,166,666 shares of its common stock at a public offering price of $3.00 per share. All of the shares sold in the offering will be sold by Aptinyx. In addition, Aptinyx has granted the underwriters a 30-day option to purchase up to 1,525,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
The gross proceeds from the offering, before deducting underwriting... More
